Nemolizumab
Nemluvio (nemolizumab) is an antibody pharmaceutical. Nemolizumab was first approved as Nemluvio on 2024-08-12. It is used to treat prurigo in the USA. The pharmaceutical is active against interleukin-31 receptor subunit alpha.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Nemluvio
Drug Products
FDA
EMA
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nemluvio | Biologic Licensing Application | 2024-08-13 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | — | 6 | 4 | — | — | 10 |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 6 | 4 | — | — | 10 |
| Eczema | D004485 | HP_0000964 | L30.9 | — | 5 | 4 | — | — | 9 |
| Prurigo | D011536 | — | L28.2 | — | 1 | 4 | — | — | 5 |
| Neurodermatitis | D009450 | — | L28.0 | — | — | 4 | — | — | 4 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | 1 | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 1 | 1 | — | — | 1 |
| Pruritus | D011537 | HP_0000989 | L29 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic scleroderma | D012595 | EFO_0000717 | M34.0 | — | 1 | — | — | — | 1 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 1 | — | — | — | 1 |
| Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nemolizumab |
| INN | nemolizumab |
| Description | Nemolizumab is an experimental drug for the treatment of itching in people with atopic dermatitis. It is a monoclonal antibody that blocks the interleukin-31 receptor A. Results of a Phase II clinical trial were published in March 2017.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297794 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | GN465U8B72 (ChemIDplus, GSRS) |
Target
Agency Approved
IL31RA
IL31RA
Organism
Homo sapiens
Gene name
IL31RA
Gene synonyms
CRL3, GPL
NCBI Gene ID
Protein name
interleukin-31 receptor subunit alpha
Protein synonyms
class I cytokine receptor, Cytokine receptor-like 3, GLM-R, Gp130-like monocyte receptor, Gp130-like receptor, hGLM-R, IL-31 receptor subunit alpha, IL-31R subunit alpha, soluble type I cytokine receptor CRL3, ZcytoR17
Uniprot ID
Mouse ortholog
Il31ra (218624)
interleukin-31 receptor subunit alpha (Q8R501)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 461 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use